Clinical Trials on Infertility, Female in Spain

Total 1170 results

Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Bayer

Completed

Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II

Sexual Dysfunction | Male Erectile Dysfunction

Belgium, Italy, France, Germany, Spain, Netherlands, South Africa
OHB Neonatology Ltd.

Recruiting

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)

Finland, United States, France, Italy, United Kingdom, Germany, Canada, Ireland, Japan, Netherlands, Portugal, Spain, Sweden
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
Sanofi

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Prostate Cancer Metastatic

United Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
ImmunoGen, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Canada, Germany, China, France, Korea, Republic of, Belgium, United Kingdom, Serbia, Spain, Australia, Israel, Italy, Taiwan, Czechia, Bulgaria, Netherlands, Portugal, Poland, Russian Federation, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Approved for marketing

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Neoplasms | Genital Diseases, Male

United States, Australia, Hong Kong, Spain, Colombia, Mexico, Poland, Malaysia, Romania, Canada, Greece, Taiwan, Korea, Republic of, New Zealand, Singapore, Brazil, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary and more
Centro Nacional de Investigaciones Oncologicas...
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina...

Unknown

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223. (PRORADIUM)

Advanced Prostate Cancer | Castration Resistant | Radium 223

Spain
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
AstraZeneca

Completed

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) (UROCOR)

Prostatic Cancer

Spain
Celgene

Completed

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Neoplasm Metastasis | Prostate Cancer | Chronic Lymphocytic Leukemia | Glioblastoma Multiforme | Squamous Cell Carcinoma of Head and Neck | Ewing's Osteosarcoma

United States, Spain, France, Germany
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal
Bayer

Completed

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Prostatic Neoplasms

United States, Canada, Taiwan, Spain, Australia, Czechia, Germany, Israel, Korea, Republic of, France, Brazil, Chile, Italy, Sweden, United Kingdom
EMD Serono

Completed

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (PERSEUS)

Prostate Cancer Metastatic

United States, Australia, France, Poland, Russian Federation, Spain, Germany, Netherlands, Slovakia, Canada, South Africa, Belgium
GlaxoSmithKline

Completed

ARTS - AVODART After Radical Therapy For Prostate Cancer Study (ARTS)

Neoplasms, Prostate | Prostate Cancer After a Radical Treatment

Spain, Estonia, Netherlands, United Kingdom, Germany, Finland, France, Russian Federation, Sweden
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
Millennium Pharmaceuticals, Inc.

Completed

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Prostate Cancer

France, United States, Belgium, Spain, Australia, Canada, Netherlands, Italy, Poland, Czechia, Estonia, Finland, Hungary, Greece
Novartis Pharmaceuticals

Completed

Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Male Osteoporosis

Russian Federation, Argentina, Switzerland, United Kingdom, Germany, Belgium, Czechia, Finland, Spain, Brazil, Romania, Hungary, Denmark, Poland, Norway, Sweden, Austria, South Africa, Slovakia, Australia, Iceland, Italy, Portugal
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Cancer Research UK; European Organisation for... and other collaborators

Active, not recruiting

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Seminoma | Teratoma | Choriocarcinoma | Germinoma | Germ Cell Tumor | Yolk Sac Tumor | Mixed Germ Cell Tumor | Childhood Teratoma | Malignant Germ Cell Neoplasm | Extragonadal Seminoma | Non-seminomatous Germ Cell Tumor

United States, Germany, France, Spain, Netherlands, Australia, Belgium, Switzerland, United Kingdom, Italy, Denmark, Ireland
Prostate Cancer Clinical Trials Consortium

Recruiting

International Registry for Men With Advanced Prostate Cancer (IRONMAN) (IRONMAN)

Prostate Cancer

United States, Australia, Spain, Switzerland, United Kingdom, Kenya, Canada, Ireland, Barbados, Brazil, Jamaica, Nigeria, Norway, Sweden, South Africa
Cougar Biotechnology, Inc.

Completed

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Prostatic Neoplasms

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Canada, Austria, Netherlands, Ireland, Hungary
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer

United States, Spain
Janssen Pharmaceutica N.V., Belgium

Completed

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Prostate Cancer

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)

Prostate Cancer

United States, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Janssen Research & Development, LLC

Completed

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Canada, Netherlands, Greece, Sweden
Pfizer

Terminated

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy (SUN 1120)

Prostatic Neoplasms

United States, Canada, Spain, Belgium, Finland, Italy, Korea, Republic of, Poland, Portugal, Slovakia, Sweden, Denmark, Taiwan, China, Australia, Germany, Israel, United Kingdom, Brazil, France, Czech Republic, Peru
Sanofi

Completed

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA)

Prostate Cancer

Korea, Republic of, Spain, United States, Argentina, Peru, Romania, Taiwan, United Kingdom, Belgium, Chile, Netherlands, Australia, Germany, Tunisia, Brazil, Canada, France, Hungary, Poland, Russian Federation, South Africa, Turkey
Bristol-Myers Squibb

Completed

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY)

Prostatic Neoplasms

United States, Argentina, Czech Republic, India, Italy, Korea, Republic of, Mexico, Poland, Spain, Sweden, Germany, Australia, Canada, Peru, Russian Federation, Hungary, Ireland, South Africa, France, Brazil, Romania, United Kingdom, Finla... and more
LTN PHARMACEUTICALS, INC.

Terminated

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)

Prostate Cancer

United States, France, Australia, Canada, Spain, United Kingdom, Italy, Belgium
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Bristol-Myers Squibb

Completed

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Prostate Cancer

United States, France, Mexico, Sweden, Canada, Australia, Italy, Colombia, Denmark, Argentina, Chile, Spain, Germany, Puerto Rico, United Kingdom, Czech Republic, Romania, Norway, Poland, Netherlands, Brazil, Hungary, Turkey, Greece
Abbott

Completed

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Prostatic Neoplasms

Canada, United States, Spain, Belgium, Australia, Italy, United Kingdom, Germany, France, Sweden, South Africa, Netherlands, Ireland, New Zealand, Greece, Poland, Austria
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)

Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, Belgium, United Kingdom, Canada, China, Denmark, France, Greece, Poland, Spain, Italy, Czechia, Japan, Switzerland, Australia, Germany, Austria, Hungary, Russian Federation, Taiwan
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
Bristol-Myers Squibb

Completed

Study of Immunotherapy to Treat Advanced Prostate Cancer

Prostate Cancer

United States, Argentina, Italy, Mexico, Spain, United Kingdom, Netherlands, Australia, Colombia, Belgium, Austria, Denmark, Puerto Rico, France, Israel, Peru, Romania, Russian Federation, Hungary, Brazil, Germany, Czech Republic, C... and more
Myovant Sciences GmbH

Completed

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)

Prostate Cancer

United States, Germany, Spain, New Zealand, Brazil, Belgium, Australia, Austria, Canada, China, Denmark, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Poland, Slovakia, Sweden, Taiwan, United Kingdom
Amgen

Completed

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Poland, Switzerland, Korea, Republic of, Russian Federation, Hong Kong, Portugal, South Africa, Israel, Romania, Bulgaria, Greece, Australia, Sweden, Japan, Latvia and more
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Prostate Cancer

Sweden, United States, Brazil, France, Peru, Spain, United Kingdom, Germany, Poland, Romania, Finland, Canada, Argentina, Australia, South Africa, Czech Republic, India, Netherlands, Italy, Switzerland, Korea, Republic of, Hungary, ... and more
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland

Clinical Trials on Infertility, Female in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations